Wednesday, October 12, 2011

Easton Pharmaceuticals Inc. EAPH

Easton Pharmaceuticals Inc. EAPH



About EAPH

Easton Pharmaceuticals, Inc. is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding numbers of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.

The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.


Products and Services

Easton Pharmaceuticals' first product to market is a female sexual enhancement gel marketed under the brand name ViorraTM. Female Sexual Dysfunction (FSD) is estimated to affect 43% of women, with many women experiencing hypoactive sexual desire disorder (HSDD) or low sex drive at some point in their lives. ViorraTM has been specifically formulated to enhance the female sexual experience with safe and effective vaginal revitalization and increased stimulation.

ViorraTM is an all-natural, hormone free, non-toxic, topical gel that is endorsed by some of the world's leading medical experts on women's sexuality. The doctor recommended daily use of ViorraTM Sensuality Solution helps to restore and improve moisture and vaginal elasticity, improving sexual functioning for women. The improvement of sexual functioning of women has a positive effect on sexual desire, arousal and the ability to experience orgasms. ViorraTM is also designed to be used during sexual intimacy to enhance sexual activity by improving lubrication and providing a warm and pleasurable stimulating sensation. This unique product will be marketed as a premium cosmetic product developed specifically for women interested in maintaining and improving their sexual health and intimate relationships.



Corporate Governance

The Board of Directors of Easton Pharmaceuticals is committed to sound corporate governance and sets high standards for the management team and employees. It is the board's duty to oversee the management of the Company's business and to ensure that investors, customers, partners, and employees practice good corporate governance practices and comply with the law.

Easton Pharmaceuticals is committed to providing safe and effective products. Testing protocol is extensive for all products. Third party, multi-centre clinical trials will be completed for all products to validate efficacy statements and to give consumers confidence in the products.

ViorraTM has completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. ViorraTM has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed sexual function disorder for the past five years tested ViorraTM.

There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction.


EAPH Management Team

John Easton
Interim C.E.O.
Founder & Chairman

Mr. Easton is an accomplished entrepreneur who has assisted in the successful fundraising and launch of several new companies and has been at the helm of multi-million dollar projects in Canada for twenty-five years. He recognized the dynamic growth and untapped market potential in the health care field in the area of tissue healing and sexual wellness. He has spent the past eight years conducting extensive research and has assembled world class medical Doctors and a professional management team in preparation for the launch of Easton Pharmaceuticals. Mr. Easton will provide the vision and direction that will be the foundation of Easton Pharmaceuticals.

John Mitchell Vice President of Sales - North America
Mr. Mitchell brings years of pharmaceutical sales and marketing experience to compliment Easton Pharmaceuticals management team.

Mr. Mitchell has more than 30 years of sales and marketing experience, holding V.P. of Sales positions for several leading North American pharmaceutical and consumer products companies. Mitchell developed and implemented contract agreements for consumer promotions and OEM products for Bayer, Roche Diagnostics, Eli Lilly, Abbott, Medisense, and Lifescan, a division of J&J.

As Vice President of Sales - North America, Mr. Mitchell will create and direct key sales and marketing programs, including direct to consumer and direct response marketing plans from product sourcing, packaging, label and product claim review, and full retail sales and marketing support. Mr Mitchell will be leveraging his extensive sales channel contacts to help Easton Pharmaceuticals build key retail bridges to all major U.S and Canadian retailers, include CVS, Walgreens, GNC, Wal-Mart plus many other retail outlets.

Walter Folinski

Walter Folinski, is an accomplished businessman and entrepreneur with 30 plus years of Senior Executive international corporate experience with emphasis on business development, corporate strategy and capital raising. He still regularly consults with international company executives from a variety of business fields and countries to assist in synergistic solutions to corporate issues. Mr. Folinski has also been involved with many successful multi million dollar private ventures, including capital raising and financing management at all levels of various private and public company’s, including real estate development and building projects including the opening of several small to mid-size Casino’s throughout Europe.

Senior Vice President
Chief Medical Officer

Dr. Barkin FICS, FACS, DABU, MHM, CCPE, FRCS (c) is the past Chief Urologist and present Chief of Staff at a university affiliated Toronto hospital, and an Assistant Professor in the Department of Surgery at the University of Toronto.

Dr. Barkin is a Director of the Society of Urologic Surgeons of Ontario, Vice-President of The Canadian Society for the Study of the Aging Male, Vice- Chairman of The Canadian Male Sexual Health Council, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American College of Surgeons. He recently became one of the first “Canadian Certified Physician Executives”. He is also the Executive Deputy Editor of the Canadian Journal of Urology for whom he has recently written and edited The Update in Urology for Primary Care Practitioners, including a large article on Erectile Dysfunction and Hypogonadism. Over the past 25 years, Dr Barkin has been a principal investigator in over 125 international clinical trials on various aspects of urology, has special interests in male and female sexual function disorders, and was the keynote speaker at the Canadian press conference launch for Viagra, Cialis, and Levitra.

Dr. Barkin is also a member of numerous medical advisory boards for leading pharmaceutical companies including Pfizer, Eli Lilly, Bayer, Merck, Abbott, Jansen-Ortho, Allergan, Ferring, Paladin, GSK, Sanofi, and Astra Zeneca. Dr. Barkin’s credentials also include expert appearances on numerous notable TV shows, network programs, and speaking engagements throughout the world on all aspects of sexual function disorders. He has published extensively in numerous medical journals and is an expert reviewer for many urologic journals.He has participated in many Canadian press conferences, and helped launch many new pharmaceuticals for such companies as Jansen Ortho, Pfizer, Lilly, Solvay, Astra Zeneca and Bayer.

Lee Hendelson
Chief Finance Officer

Mr. Hendelson is a public accountant, and has been CFO and Controller for various companies during the past 35 years. He built a successful accounting firm in the United States by providing specializes accounting services, tax problems resolution, tax preparation for individuals, businesses and estates, due diligence, forecasting and pro-forma financial statements for business plans. He has a unique ability in the formulation, compilation and organization of financial data along with his forensic accounting abilities, he knows what pitfalls companies fall into as they grow and assists in avoiding those issues. He played an integral part in the filings of financial statements for various publicly traded companies. He acted in the capacity of Trustee for many private clients and their financial advisors. He worked closely with various venture capital firms in New York City and Palm Beach Florida analyzing profitability for portfolio c lients. He attended City University of New York and received his Bachelors of Science in Accounting. In his capacity as Chief Financial Officer, Mr. Hendelson will provide direction for all financial matters for Easton Pharmaceuticals.

Susan Whyte
Vice President of Marketing

Ms. Whyte brings over 20 years of successful consumer packaged goods marketing experience to the Easton Pharmaceuticals management team. She has managed and led the branded product initiatives for several North American organizations including the launch of several new products in the cosmetic and retail grocery industries. She has experience in managing start-ups, strategic planning, product development, consumer insights research, web site development, marketing promotions, public relations campaigns and has made public appearances on television and radio talk shows.

Dr. Asa Hershoff
Senior Consultant to Research and Development

Dr. Hershoff is a highly recognized Naturopathic Physician and Chiropractor with over 35 years of specialization in herbal and homeopathic medicine. He is a graduate of the Canadian Memorial Chiropractic College and the Canadian College of Naturopathic Medicine and has offices in Los Angeles and New York. He was Chief medical consultant/lecturer for Boericke & Tafel for 7 years (America’s oldest homeopathic pharmacy) .Medical consultant and lecturer for Dolisos, BHI/Heel, Seroyal Canada, NaturPharm, Nu-Life (Canada’s largest supplement manufacturer), Hobon, Natraceuticals, Energetique, He has formulated over 250 homeopathic, vitamins and herbal remedies that are currently sold in most pharmacies in the USA and Canada. Author of 3 books on Homeopathy for Musculoskeletal Healing, Homeopathic Remedies and Herbal Remedies. Graduate, Canadian Memorial Chiropractic College (D.C.), 1974; top of class of 100 in his second ye ar. Diplomat of the Homeopathic Academy of Naturopathic Physicians (DHANP), 1998. Dr. Hershoff will utilize his expertise in natural medicines to direct the R&D program for Easton Pharmaceuticals.



Monday, September 26, 2011
Easton Pharmaceuticals Strengthens Sales Capabilities With Key Management Team Addition
Marketwire (Mon, Sep 26)

Thursday, September 22, 2011
Easton Pharmaceuticals Announces Retaining Winston & Strawn For Patent Application Submission
Marketwire (Thu, Sep 22)

Quote: Winston & Strawn is a large multinational law firm. The firm's patent attorneys, including those based in Washington, D.C., are well versed with all types of patent filings including pharmaceutical and OTC transdermal type of products such as the "Viorra" brand product.

Wednesday, September 21, 2011
Easton Pharmaceuticals Announces Receiving Two Financing Proposals
Marketwire (Wed, Sep 21)

Thursday, September 15, 2011
Easton Pharmaceuticals Announces It has Entered into Discussions For Distribution Agreement In East Asia
Marketwire (Thu, Sep 15)

Quote: Presently the company has entered into discussions with two groups for the sale and distribution of VIORRA. Any agreements will involve an upfront payment to Easton, presently being discussed by all parties.

Tuesday, September 13, 2011
Easton Pharmaceuticals to Enter Into Clinical Safety Trials of VIORRA for North American Market
Marketwire (Tue, Sep 13)

Tuesday, August 2, 2011
Easton Pharmaceuticals Announces Update On Patents
Marketwire (Tue, Aug 2)

Quote: After interviewing several highly competent well established firms, Easton Pharmaceuticals confirms it has sourced out and retained a patent firm based in Washington, D.C. to file patents on behalf of Easton which will cover its main product 'Viorra', its proprietary transdermal delivery system and other components of 'Viorra'. The patents are deemed necessary to protect Easton's proprietary formulas and assets as it moves forward with regulatory filings in Mexico and other parts of Latin America, prior to launch in North America. Easton will release formal announcements on the patent firm and the process in due course.

Friday, July 22, 2011
Easton Pharmaceuticals Announces Projections of $15 Million in Revenue For 2012 From The Company's First Territory Launch of VIORRA in Mexico
Marketwire (Fri, Jul 22)



EAPH Contact Info

Easton Pharmaceuticals, Inc.
425 University Ave
Suite 500
Toronto, ONT M5G1T6

Phone: Toronto: 416-619-0291 - New York: 347-284-0192

Media Relations:
Investor Relations:
Product Information:
Human Resources:

As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence

Sources:,,, EAPH website,

Follow Us on Facebook